Findings

What do systematic reviews say?

643 questions · 671 findings · 87 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 177 · 26.4%GRADE not reported 106 · 15.8%Very low 182 · 27.1%Low 114 · 17%Moderate 66 · 9.8%High 26 · 3.9%

Manual therapy, prescribed exercises or both vs no intervention or minimal intervention

PainScale: VAS (0 to 10, 0 is no pain) · lateral elbow pain

1 finding from 1 review

Manual therapy and exercise for lateral elbow pain 2024 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 1023 participants
Low

Manual therapy, prescribed exercises or both vs no intervention or minimal intervention

DisabilityScale: 0 to 100 (0 is no disability) · lateral elbow pain

1 finding from 1 review

Manual therapy and exercise for lateral elbow pain 2024 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 732 participants
Low

Summary of findings table ‐ Pseudophakia vs aphakia

Visual acuity · children younger than two years of age with bilateral congenital cataracts

1 finding from 1 review

Surgical interventions for bilateral congenital cataract in children aged two years and under 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Very low

Summary of findings table ‐ Pseudophakia vs aphakia

Visual axis opacification · children younger than two years of age with bilateral congenital cataracts

It is very uncertain whether summary of findings table ‐ Pseudophakia changes visual axis opacification compared with aphakia (very low certainty).

1 finding from 1 review

Surgical interventions for bilateral congenital cataract in children aged two years and under 2022 · Cochrane Headline outcomes only
RR 1.29 [0.23, 7.13]
1 study · 54 participants
Very low

Summary of findings table ‐ Pseudophakia vs aphakia

Amblyopia ‐ not reported · children younger than two years of age with bilateral congenital cataracts

The review found no eligible studies for this question.

1 finding from 1 review

Surgical interventions for bilateral congenital cataract in children aged two years and under 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Pseudophakia vs aphakia

Glaucoma at 5 years · children younger than two years of age with bilateral congenital cataracts

It is very uncertain whether summary of findings table ‐ Pseudophakia changes glaucoma at 5 years compared with aphakia (very low certainty).

1 finding from 1 review

Surgical interventions for bilateral congenital cataract in children aged two years and under 2022 · Cochrane Headline outcomes only
RR 0.86 [0.24, 3.1]
1 study · 54 participants
Very low

Summary of findings table ‐ Pseudophakia vs aphakia

Retinal detachment ‐ not reported · children younger than two years of age with bilateral congenital cataracts

The review found no eligible studies for this question.

1 finding from 1 review

Surgical interventions for bilateral congenital cataract in children aged two years and under 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Pseudophakia vs aphakia

Reoperation rate ‐ not reported · children younger than two years of age with bilateral congenital cataracts

The review found no eligible studies for this question.

1 finding from 1 review

Surgical interventions for bilateral congenital cataract in children aged two years and under 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Pseudophakia vs aphakia

Adverse events · children younger than two years of age with bilateral congenital cataracts

1 finding from 1 review

Surgical interventions for bilateral congenital cataract in children aged two years and under 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Very low

Botulinum toxin vs placebo

Participant‐reported improvement in sialorrhea in the short term · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

Botulinum toxin injection showed no clear difference in participant‐reported improvement in sialorrhea in the short term… compared with placebo (low certainty).

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
RR 3 [0.81, 11.08]
1 study · 18 participants
Low

Dextromethorphan and quinidine sulfate combination (DMQ) vs placebo

Reduction in the amount of saliva production in the short term using an objective measure · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 participants
Very low

Dextromethorphan and quinidine sulfate combination (DMQ) vs placebo

Quality of life · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dextromethorphan and quinidine sulfate combination (DMQ) vs placebo

Adverse events · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 participants
Moderate

Scopolamine (hyoscine) patches vs placebo

Participant‐reported improvement in sialorrhea in the short term · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
8 participants
Very low

Scopolamine (hyoscine) patches vs placebo

Reduction in the amount of saliva production in the short term using an objective measure · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
8 participants
Very low

Scopolamine (hyoscine) patches vs placebo

Quality of life · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Scopolamine (hyoscine) patches vs placebo

Adverse events · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
10 participants
Very low

Botulinum toxin vs placebo

Reduction in the amount of saliva production in the short term using an objective measure · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Moderate

Botulinum toxin vs placebo

Health‐related quality of life Assessed by: SeiQoL‐DW (higher scores mean better quality of life) · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Low

Botulinum toxin vs placebo

Adverse effects · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

Botulinum toxin injection may leads to lower adverse effects compared with placebo (low certainty).

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low